Chemistry:Aprocitentan
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Other names | ACT-132577 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H14Br2N6O4S |
Molar mass | 546.19 g·mol−1 |
3D model (JSmol) | |
| |
|
Aprocitentan is an endothelin receptor antagonist active at both endothelin A and endothelin B receptors.[1] It is developed for resistant hypertension by Idorsia, which sold it to Janssen but purchased the rights back in 2023 for $343 million.[2]
Aprocitentan is an active metabolite of macitentan.[3]
References
- ↑ Ojha, Utkarsh; Ruddaraju, Sanjay; Sabapathy, Navukkarasu; Ravindran, Varun; Worapongsatitaya, Pitchaya; Haq, Jeesanul; Mohammed, Raihan; Patel, Vinod (2022). "Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension". American Journal of Cardiovascular Drugs 22 (3): 271–285. doi:10.1007/s40256-021-00510-9. PMID 34878631.
- ↑ Deswal, Phalguni (6 September 2023). "Idorsia reacquires aprocitentan rights from Janssen for $343m". Pharmaceutical Technology. https://www.pharmaceutical-technology.com/news/idorsia-reacquires-aprocitentan-rights-from-janssen-for-343m/.
- ↑ Template:Pubchem
![]() | Original source: https://en.wikipedia.org/wiki/Aprocitentan.
Read more |